AASLD 2026: Gilead Eyes Wider Livdelzi Use As Phase III Data Bolster PBC Expansion Plans Scrip Pharma Intelligence 3d
Korea approves Gilead's Livdelzi for primary biliary cholangitis Korea Biomedical Review 05:58 Wed, 21 Oct
Dr. Reddy's generic HIV prevention shot wins tentative FDA approval at $40 a year in 120 countries Medical Daily 4d HIV FDA Biotech All sources
Gilead seeks wider use for Livdelzi on Phase III liver disease success Clinical Trials Arena 2d Livdelzi Pharma Biotech All sources
Gilead Sciences has raised its dividend for 11 straight years. Here's why the streak looks safe. The Motley Fool 3d Pharma
Texas continues to target Pharma patient support programs under the Texas Anti-Kickback Statute JD Supra 1d Texas Pharma Biotech
ANI to expand its rare disease portfolio with Egetis takeout Scrip Pharma Intelligence 2d FDA Mergers and Acquisitions Rare Diseases
6 biotech stocks for a volatile bull market: Jon Erlichman BNN Bloomberg 2d Bull Market Biotechnology
CBI FIR against waste management company Hanjer Biotech for defrauding bank of $10 million under guise of setting up recycling plant in UK; 2nd fraud case The Times of India 2d Biotech Mumbai India
